BridgeBio Pharma, Inc. announced a $200m venture financing on 2 May that will enable portfolio oncology firm TheRas to spin out as BridgeBio Oncology Therapeutics (BBOT), a private and independent entity in which the corporate parent will own a less-than-50% equity stake. The move enables BBOT to focus on its KRAS- and PI3K-targeting cancer candidates – one in Phase I and the others in late preclinical development – while BridgeBio saves cash and focuses on the expected approval of Bayer AG-partnered acoramidis in November and other proprietary pipeline assets.
Key Takeaways
-
BridgeBio spins out KRAS-focused cancer firm TheRas into BridgeBio Oncology Therapeutics, while raising a $200m funding round for the new company.
-
BBOT will be...
BBOT’s immediate priority is continuing enrollment in the Phase I ONKORAS-101 study of BBO-5520, a KRAS G12C inhibitor, in KRAS G12C-mutated non-small cell lung cancer (NSCLC). The company thinks the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
